Marcos Luján Galán
Head of the Urology Unit at the Infanta Cristina Hospital, researcher in the Spanish branch of the European Randomized Study of Screening for Prostate Cancer
The study is of good quality and is in line with the evidence already known.
Mass screening for prostate cancer with PSA only produces changes in the incidence of the disease, little or no change in prostate cancer mortality and has no effect on all-cause mortality (overall mortality), since it does not add life expectancy.
The future of screening is now to include tests that reduce overdiagnosis, such as the use of magnetic resonance imaging (although its feasibility in terms of cost may be a limitation). Studies that validate screening strategies in prostate cancer require a long follow-up time (e.g. >10 years), so it will take time to see results (if they occur).